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Abstract
Diacylglycerol (DAG)-mediated signaling pathways, such as those mediated by protein kinase C (PKC), are central in
regulating cell proliferation and apoptosis. DAG-responsive C1 domains are therefore considered attractive drug targets.
Our group has designed a novel class of compounds targeted to the DAG binding site within the C1 domain of PKC. We
have previously shown that these 5-(hydroxymethyl)isophthalates modulate PKC activation in living cells. In this study we
investigated their effects on HeLa human cervical cancer cell viability and proliferation by using standard cytotoxicity tests
and an automated imaging platform with machine vision technology. Cellular effects and their mechanisms were further
characterized with the most potent compound, HMI-1a3. Isophthalate derivatives with high affinity to the PKC C1 domain
exhibited antiproliferative and non-necrotic cytotoxic effects on HeLa cells. The anti-proliferative effect was irreversible and
accompanied by cell elongation. HMI-1a3 induced down-regulation of retinoblastoma protein and cyclins A, B1, D1, and E.
Effects of isophthalates on cell morphology, cell proliferation and expression of cell cycle-related proteins were different
from those induced by phorbol 12-myristate-13-acetate (PMA) or bryostatin 1, but correlated closely to binding affinities.
Therefore, the results strongly indicate that the effect is C1 domain-mediated.
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Introduction
The protein kinase C (PKC) family of serine/threonine kinases
consists of ten known isozymes that can be divided into three
classes based on their regulatory domain structure and activation
properties [1]. The classical PKCs (a, bI, bII and c) and novel
PKCs (d, e, g and h) contain a duplicated diacylglycerol (DAG)
and phorbol-responsive C1 domain, whereas the single C1 domain
of atypical PKCs (f and i/l) does not respond to DAG or phorbol
esters. PKC C1 domains are cysteine-rich sequences that are
approximately 50 amino acids long and are located within the
regulatory region of the enzyme. They are folded into zinc finger-
like structures that respond to increased DAG levels at the plasma
membrane, leading to relocation and activation of PKC isoforms.
DAG is generated by phospholipase C-mediated hydrolysis of
phosphatidylinositol-4,5-bisphosphate (PIP2) after activation of G
protein-coupled receptors or receptor tyrosine kinases [2].
Alternatively, it can be produced indirectly from phosphatidyl-
choline via phospholipase D and phosphatic acid phosphatase [2].
Phorbol esters are diterpene-structured natural compounds that
mimic DAG actions but with significantly higher potency [3].
PKC is implicated in the regulation of various cellular functions,
such as differentiation, proliferation, apoptosis, motility and
malignant transformation [4]. However, substrates and physio-
logical roles of individual isozymes are still mostly unknown. PKCs
have been the subject of intensive research and drug development
since the discovery that they are receptors for tumor-promoting
phorbol esters. Specifically, PKC is considered a potential cancer
drug target due to its role in cell proliferation and apoptosis. This
hypothesis has been strengthened by findings of abnormal PKC
expression levels and/or aberrant PKC activity in various cancer
types [5]. In addition to cancer, PKC plays a role in several other
diseases, including cardiovascular diseases, diabetic complications,
and Alzheimer’s disease [6–8].
C1 domains of classical and novel PKC isozymes represent the
first recognized effectors for the physiological second messenger
DAG and tumor-promoting phorbol esters [1,2], and for a long
time PKCs were considered the only phorbol ester effectors.
However, DAG/phorbol-responsive C1 domains have been found
in the following six other classes of proteins: (1) protein kinase D
(PKD) family; (2) DAG kinases (DGKs); (3) Ras guanyl nucleotide-
releasing proteins (RasGRPs); (4) chimaerins; (5) Munc13
scaffolding proteins; and (6) myotonic dystrophy kinase-related
Cdc42-binding kinases (MRCKs) [9,10]. Although physiological
roles of non-PKC phorbol ester receptors have been only partially
elucidated, signaling pathways regulated by these proteins are
central in controlling various cellular functions thereby affecting
many pathological conditions. Particularly, several C1 domain-
containing proteins participate in regulating cell proliferation,
apoptosis and/or motility, thus these proteins might be implicated
in cancer [4].
The C1 domain is regarded as an attractive drug target because
PKCs and other DAG-responsive C1 domain-containing proteins
play key roles in controlling cell proliferation, apoptosis, and
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motility [11]. Various C1 domain ligands have been described,
including some obtained from natural sources and others based on
synthesized chemical entities (reviewed in [12]). Several C1
domain-binding compounds, such as the natural compounds
bryostatin 1 and ingenol-3-angelate (PEP005), have entered
clinical trials for the treatment of different cancers [13]. However,
most C1 domain ligands are structurally complex so modification
and large-scale production may be unfeasible. Our group has
developed a novel class of synthetic C1 domain ligands, dialkyl 5-
(hydroxymethyl)isophthalates, which are fairly easily synthesized
with good yields, bind to the phorbol ester binding site within the
PKC C1 domain, and modulate PKC activity in living cells [14].
The purpose of this study was to examine effects of nine
isophthalate derivatives on HeLa human cervical cancer cell
viability and proliferation and to further characterize cellular
effects of one of the active derivatives.
Results
Compound selection
To evaluate effects of isophthalate derivatives on HeLa cell
viability and proliferation, we selected compounds based on our
previous studies with over 40 compounds [14]. Five compounds
were selected for their high binding affinity to the C1 domain
(‘‘active’’ compounds; HMI-1a3, HMI-1b1, HMI-1b2, HMI-
1b10, and HMI-1b11) and four compounds were selected that
had poor binding affinity (‘‘inactive’’ compounds; HMI-1b20, NI-
15e, HMI-24a, and HMP-27). Compound structures and their
binding affinities to PKCa and PKCd are shown in Figure 1.
Additionally, the well-characterized C1 domain ligands phorbol
12-myristate-13-acetate (PMA) and bryostatin 1 were used as
reference compounds.
Effects of isophthalates on HeLa cell viability
HeLa cells were exposed to isophthalate derivatives for 24 or
48 h, and cell viability was studied using standard LDH and MTT
tests. A 24-h exposure to HMI-1a3 or HMI-1b1 at concentrations
of $1 mM or $4 mM, respectively, induced cell viability
reductions that were greater than 50% (Fig. 2A, p,0.001). In
addition, compounds HMI-1b2 (4–20 mM, p,0.001), HMI-1b11
(20 mM, p,0.01), and HMI-1b10 (20 mM, p,0.05) induced
statistically significant cytotoxicity after a 24-h treatment
(Fig. 2A). No significant toxicity was observed after exposure to
compounds HMI-1b20, NI-15e, HMI-24a, and HMP-27 (Fig. 2A).
MTT tests after a 48-h treatment gave similar results (data not
shown). In contrast, bryostatin 1 had no significant effect on HeLa
cell viability (p = 0.964; Fig. 2B). PMA exhibited only weak
toxicity; it induced a 30% reduction in cell viability at 10 nM
(p,0.01) and 20% reductions in viability at 0.1–1 mM that were
however not statistically significant (Fig. 2B). In contrast to MTT
assay results, LDH tests showed no significant cytotoxicity with
any compound. Specifically, cytotoxicity measured by the LDH
test was always less than 10% (data not shown).
Inhibition of thymidine incorporation by HMI-1a3
On the basis of the cell viability studies we chose the most potent
compound HMI-1a3 for studying its effects on thymidine
incorporation. Exposures to HMI-1a3 for 6 and 24 h inhibited
the incorporation of [methyl-3H]thymidine into HeLa cells in a
concentration-dependent manner (Fig. 3A). The EC50 values for
HMI-1a3 were 5.8 mM and 4.5 mM for the 6 and 24 h incubations,
respectively. However, HMI-1a3 concentrations of 0.1 mM and
1 mM increased thymidine incorporation by 25–50% after both
exposure durations. PMA inhibited thymidine incorporation with
an EC50 value of 1.9 nM after a 24-h treatment (Fig. 3B). Similar to
HMI-1a3, the smallest PMA concentrations of 0.01 nM and
0.1 nM induced a 25–30% increase in thymidine incorporation.
Effects of isophthalates on HeLa cell proliferation
A continuous cell culturing platform with integrated phase
contrast optics (Cell-IQH) was used to study the effects of
isophthalates on HeLa cell proliferation in more detail. Active
compounds inhibited cell proliferation in a concentration-
dependent manner (Fig. 4A and 4B). After a 72-h treatment,
statistically significant inhibition was measured for the following
compounds compared to untreated HeLa cells (Fig. 4A): HMI-1a3
at 4–20 mM (p,0.001); HMI-1b1 and HMI-1b2 at 10–20 mM
Figure 1. Structures and binding affinities of isophthalate derivatives. Binding affinity is expressed as mean 6 SEM (n= 3–8) of the
inhibition percentage of [3H]phorbol-12,13-dibutyrate ([3H]PDBu) binding at compound concentrations of 20 mM. Binding data are from [14] and are
reprinted with permission from the American Chemical Society.
doi:10.1371/journal.pone.0020053.g001
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(p,0.001 and p,0.01, respectively); and HMI-1b11, HMI-1b10
and HMI-24a at 20 mM (p,0.05). Compounds HMI-1b20, NI-
15e and HMP-27 had no effect on HeLa cell proliferation
(Fig. 4A). The concentration-dependent effect of HMI-1a3 was
detectable for the duration of the experiment (Fig. 4B), and this
pattern was also detected among other compounds that inhibited
cell proliferation (data not shown). The proliferation rate of HeLa
cells exposed to inactive compounds did not differ from untreated
cells at any time point (HMP-27 shown as an example in Fig. 4B).
Despite the fact that PMA inhibited thymidine incorporation in
HeLa cells, it had no anti-proliferative effect in HeLa cells in Cell-
IQH experiments (Fig. 4C).
Effects of isophthalates and PMA on HeLa cell
morphology
Active isophthalates, such as HMI-1a3, induced changes in
HeLa cell morphology that were characterized by cell elongation
and reduced cell-to-cell contacts (Fig. 5), while inactive compounds
had no effect (HMP-27 shown in Fig. 5). This observation led us to
develop a protocol for Cell-IQ AnalyzerH software for quantifying
the morphological changes (see experimental section for details). In
untreated wells and inactive compound-treated wells (e.g., HMP-
27) the proportion of apparently healthy cells remained the same
or decreased slightly and the proportion of dividing and dead cells
increased only slightly during the 72-h exposure (Fig. 5, J–K).
However, the proportion of apparently healthy cells decreased
immediately and rapidly in wells treated with 20 mM of HMI-1a3
(Fig. 5L). This decline was accompanied with an increase in the
proportion of elongated cells and a delayed increase in the
proportion of dead cells. Elongated cells constituted the majority
after 22 h, and dead cells dominated wells after 40 h of exposure.
At 10 mM concentration HMI-1a3 induced similar changes in cell
morphology, although at a slower rate (data not shown). In
addition, the proportion of dead cells never exceeded the
proportion of elongated cells in wells treated with 10 mM of
HMI-1a3. Other active compounds (HMI-1b1, HMI-1b2, HMI-
1b10, and HMI-1b11) also induced cell elongation at concentra-
tions that inhibited cell proliferation (data not shown). However,
compound HMI-24a, which inhibited proliferation of HeLa cells
to some extent at the highest concentration (20 mM) (Fig. 4A),
induced only slight changes in cell morphology (data not shown).
HMI-1a3-induced cell elongation and cell death were not affected
Figure 2. Effects of C1 domain ligands on HeLa cell viability. Cells were exposed to isophthalate derivatives (A) and PMA or bryostatin 1 (B)
for 24 h, and cell viability was determined by MTT assay. Results are expressed as mean + SEM (n = 3–6; n = 2 for the HMI-24a group).
doi:10.1371/journal.pone.0020053.g002
Figure 3. Inhibition of [3H-methyl]thymidine incorporation by HMI-1a3 and PMA. HeLa cells were treated for 6 or 24 h with increasing
concentrations of HMI-1a3 (A) or PMA (B), and the incorporation of thymidine was determined. Error bars indicate SEM from 3 independent
experiments.
doi:10.1371/journal.pone.0020053.g003
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Figure 4. Effects of isophthalate derivatives and PMA on HeLa cell proliferation. HeLa cells were treated with test compounds and
photographed automatically for 72 h with Cell-IQH. Cell numbers were quantified from each image using Cell-IQ AnalyzerH software. A, normalized
total cell number at 72 h is expressed as a percentage of control. Results represent mean + SEM from 3–5 independent experiments except for NI-15e
where n = 2. B and C, proliferation of HeLa cells during the 72-h experiment is shown as normalized total cell number in untreated wells and after
treatment with different concentrations of HMI-1a3 and HMP-27 (B) and PMA (C). Cell numbers shown were determined from images taken with 3-h
intervals from a single, representative experiment. Error bars correspond to SEM of 4 images taken from different positions within the same well.
Experiments were repeated at least 3 times with similar results.
doi:10.1371/journal.pone.0020053.g004
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Figure 5. Effect of isophthalate derivatives on HeLa cell morphology. Untreated cells (A, D, G) and cells treated with 20 mM of HMP-27 (B, E,
H) or 20 mM of HMI-1a3 (C, F, I) were imaged automatically for 72 h with Cell-IQH and analyzed using Cell-IQ AnalyzerH software. Representative
photomicrographs taken at time points 0 h (A–C), 24 h (D–F) and 72 h (G–I) are presented. J–M, quantification results from a single, representative
experiment (mean from 4 images in different positions within the same well) of untreated cells (J) and cells treated with 20 mM of HMP-27 (K), 20 mM
of HMI-1a3 (L) or 20 mM of HMI-1a3 and 40 mM of BAF. Experiments were repeated at least 3 times with similar results.
doi:10.1371/journal.pone.0020053.g005
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by co-exposure to the pan-caspase inhibitor Boc-Asp(OMe)
fluoromethyl ketone (BAF; Fig. 5M).
PMA induced a different pattern of morphological changes in
HeLa cells compared to isophthalate-induced changes. More
specifically, it evoked a transient elongation that was visible at 12–
30 h after the beginning of the experiments, as well as cell rounding
that was persistent throughout the experiments (Fig. 6). In contrast
to isophthalate-treated cells, in which elongation was accompanied
with permanent growth arrest, cells that were elongated after PMA
treatment recovered and continued dividing (Fig. 6).
The effects of HMI-1a3 on HeLa cell proliferation and
morphology are irreversible
To determine whether cellular effects of HMI-1a3 were
reversible, HeLa cells were treated with 20 mM of HMI-1a3 for
1, 8 or 24 h, washed twice with PBS, and grown in fresh medium
for an additional 72 h (total duration of experiment was 96 h).
Untreated cells and cells treated with HMI-1a3 for the duration of
the experiment were used as controls. Cells were inspected daily
with a microscope, and cell morphology and proliferation were
assessed visually. After a 24-h treatment with 20 mM of HMI-1a3
followed by a 72-h incubation period in normal medium, cell
morphology and proliferation rate were identical to those treated
with 20 mM of HMI-1a3 for the duration of the experiment, i.e.
most cells were elongated and unable to divide or were dead (data
not shown). In wells exposed to HMI-1a3 for 8 h, only a fraction
of cells was elongated and unable to divide, while the remainder of
cells continued to proliferate. At the end of the experiment, there
were fewer cells than in untreated wells, but considerably more
cells than in wells treated with HMI-1a3 for 24 or 96 h (data not
Figure 6. Effect of PMA on HeLa cell proliferation and morphology. HeLa cells treated with PMA (1 nM–1 mM) were imaged for 72 h with
Cell-IQH. Representative photomicrographs taken at time points 0, 24 and 72 h are presented. Experiments were repeated 3 times with similar results.
doi:10.1371/journal.pone.0020053.g006
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shown). A one-hour exposure to 20 mM of HMI-1a3 induced only
slight reductions in cell density and few cell elongations with most
cells appearing normal and healthy (data not shown).
HMI-1a3-induced changes in the expression of cell cycle
markers are different from those induced by PMA or
bryostatin 1
Effects of a 24-h treatment with HMI-1a3 on the expression of
cell cycle markers were studied and compared to those of PMA
and bryostatin 1. Representative blots are shown in Fig. 7A and
the quantification results are provided in Fig. 7B. At HMI-1a3
concentrations of 10 mM and 20 mM, down-regulation was
observed among all cyclins tested (i.e., cyclin A, cyclin B1, cyclin
D1, and cyclin E), and decreases in amounts of retinoblastoma
(Rb) protein and phosphorylated Rb (pRb) were detected.
Additionally, 10 mM of HMI-1a3 down-regulated p21waf1/cip1
and p27kip1 proteins, but these effects were not visible at 20 mM.
Effects of HMI-1a3 were completely different from PMA and
bryostatin 1. Both of these reference compounds down-regulated
cyclin A and p27, had no effect on cyclin B1, total Rb and pRb,
strongly up-regulated cyclin D1 and p21, and slightly up-regulated
cyclin E (Fig. 7A and 7B).
Discussion
In efforts to develop drugs to treat PKC-related diseases,
targeting the C1 domain has some advantages over the traditional
approach of targeting the catalytic site. For example, it provides a
possibility of developing activators. It also decreases the number of
possible target proteins thus increasing chances for selectivity.
Moreover, in addition to its catalytic activity PKC has noteworthy
non-catalytic functions [15]. For instance, it has been shown that
the pro-proliferative and pro-survival role of PKCa in several
glioma cell lines is not dependent on kinase activity, but is rather
dependent on the protein itself as a non-catalytic scaffold protein
[16]. Furthermore, a conserved sequence N-terminal of the C1b
domain of PKCe has been shown to be responsible for the
induction of neurite-like processes in neuroblastoma cells [17,18].
We have previously described properties of a novel group of C1
domain ligands, dialkyl 5-(hydroxymethyl)isophthalates [14]. In
the present study, we showed that effects of selected isophthalates
on HeLa cell viability and proliferation correlated well with the
previously developed structure-activity model that was based on
binding affinities. Compounds with good binding affinity to C1
domains of PKCa and PKCd inhibited HeLa cell proliferation
and induced cytotoxicity, while derivatives with poor binding
affinity had no effect. Therefore, effects are probably mediated by
either PKC or some other protein containing a DAG/phorbol-
responsive C1 domain. Despite relatively similar binding affinities
to PKCs, active compounds affected HeLa cell viability and
proliferation at different potencies. For example, HMI-1a3 and
HMI-1b11 bind to PKCa and PKCd with comparable affinities
[14], but HMI-1b11 exerts significantly less toxicity to HeLa cells.
This observation is consistent with our previous studies showing
that HMI-1a3 induced ERK1/2 activation in a PKC-dependent
manner, and HMI-1b11 alone was unable to induce ERK1/2
phosphorylation but rather inhibited PMA-evoked ERK1/2
phosphorylation [14]. This difference between the compounds
could be due to different outcomes associated with binding to the
target protein (activation or inhibition) or different binding
affinities to the target protein if the effect is mediated by a non-
PKC phorbol ester receptor.
Natural C1 domain ligands PMA and bryostatin 1 that were
used as reference compounds had no or only weak effects on HeLa
cell viability. PMA-induced decrease in cell viability was
statistically significant only at 10 nM concentration, and there
Figure 7. Effects of C1 domain ligands on the expression of cell cycle markers. HeLa cells were exposed to compounds for 24 h and
proteins were detected with Western blotting. A, representative Western blots showing specific immunoreactive bands after various treatments
(lanes 1–6) as follows: lane 1, untreated cells; lane 2, 0.2% DMSO; lane 3, PMA at 100 nM; lane 4, bryostatin 1 at 100 nM; lane 5, HMI-1a3 at 10 mM;
lane 6, HMI-1a3 at 20 mM. B, quantification results of Western blots expressed as mean + SEM (n= 3-4). OD=optical density.
doi:10.1371/journal.pone.0020053.g007
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was no clear antiproliferative effect at concentrations used in this
study (1 nM-1 mM). Depending on the cell type, PMA may have
opposing effects on cell proliferation and apoptosis [19]. Bryostatin
1 on the other hand has been reported to have little effect on HeLa
cell proliferation [20], which was supported by our data from cell
viability assays, and therefore it was not included in Cell-IQH
experiments.
Results from cell viability studies and Cell-IQH experiments also
indicate that the mechanism of isophthalate-induced cytotoxicity is
non-necrotic because cytotoxic effects were observed only in the
MTT assay and not the LDH assay, which measures cell
membrane integrity [21]. Additionally, the mechanism of
isophthalate-induced cell death seems to be caspase-independent
because the pan-caspase inhibitor BAF had no effect on the
kinetics of HeLa cell death in Cell-IQH studies. Generally, caspase
inhibitors decelerate the process of apoptotic cell death even
though they are not able to prevent it [22,23].
Thymidine incorporation assays with HMI-1a3 showed that the
onset of the effect was rapid. Specifically, even a 6-h exposure to
HMI-1a3 inhibited thymidine incorporation, although not as
efficiently as a 24-h exposure. HMI-1a3-induced inhibition of
thymidine incorporation at concentrations of $4 mM was
consistent with the results from Cell-IQH analysis. However, the
increase in thymidine incorporation observed at the lowest HMI-
1a3 and PMA concentrations was contrasted with results from
Cell-IQH time-lapse analysis. Specifically, the lowest concentra-
tions of PMA and HMI-1a3 did not significantly increase cell
proliferation at any time point upon analysis by Cell-IQH. Thus,
increases in thymidine incorporation do not necessarily reflect
actual increases in cell proliferation. Furthermore, inhibition of
thymidine incorporation at PMA concentrations of $100 nM
were not supported by results from Cell-IQH analysis, where PMA
exposure was shown to have no prominent effect on HeLa cell
proliferation.
While studying proliferation of HeLa cells with Cell-IQH, we
observed that compounds that inhibited cell proliferation also
induced cell elongation. These cell elongations were characterized
by narrowed cell bodies, elongated cell processes, and reduced
cell-to-cell contacts. Similar changes in HeLa cell morphology
have been recently reported as a consequence of knock-down of
prohibitin [24], which plays important roles in mitochondrial
function and regulating PI3K/Akt, Ras/ERK and TGF-b
signaling pathways [25]. Elongated HeLa cell morphology has
also been reported after chronic exposure to increasing concen-
trations of DMSO (0.5–2%) [26]. This study also used DMSO as
the co-solvent for all compounds tested. However, DMSO
concentrations were always #0.4% and had no effect on cell
morphology or proliferation. Regarding C1 domain-containing
proteins, PKCs, DGKs, chimaerins and MRCKs have been
shown to participate in controlling cytoskeleton reorganization
[27,28] and thus may be responsible for mediating changes in cell
morphology induced by isophthalates. The fact that PMA also
induced cell elongation supports the hypothesis that the morpho-
logical changes are mediated by a DAG effector. However, PMA-
induced cell elongation was transient and it was accompanied with
emergence of rounded cells, a phenomenon not seen in
isophthalate-treated cells. This may be due to different outcome
(activation/inactivation/down-regulation) of ligand binding to its
target. For example, C1 domain ligands are known to induce
different patterns of PKC down-regulation [29,30]. Phorbol esters
and bryostatin 1 induce permanent activation of PKC isoforms,
which eventually leads to their down-regulation and thus
inhibition of kinase activity. Transient (such as DAG-induced)
PKC activation on the other hand does not induce down-
regulation. Furthermore, the existence of several classes of
phorbol/DAG-responsive C1 domain-containing proteins and
the cross-talk of their signaling pathways adds an additional layer
of complexity to this issue.
Observations of higher proportions of elongated and non-
dividing cells with longer exposure times to HMI-1a3 suggest that
HMI-1a3 may exert its effects at a certain phase of the cell cycle,
so that only cells in a specific cell cycle phase might be affected by
treatments. This idea is supported by results showing that a 6-h
treatment with HMI-1a3 was unable to completely block
thymidine incorporation, suggesting that HMI-1a3 may not be
able to inhibit ongoing DNA synthesis. Rather, it may induce cell
cycle arrest just before cells enter the S phase. Therefore, we also
studied effects of HMI-1a3 on the expression of several proteins
related to cell cycle progression (reviewed in [31,32]). Typically,
D-type cyclins are expressed throughout the cell cycle, while
cyclins A, B and E are expressed in a periodical manner: cyclin A
is expressed in S and G2 phases of the cell cycle; cyclin B is
expressed in S, G2 and M phases; and cyclin E expression is
induced in late G1 phase. During G1/S transition Rb is
inactivated by phosphorylation, leading to cell cycle progression.
The cyclin-dependent kinase inhibitors p21 and p27 typically
induce cell cycle arrest in G1 phase. Exposure to HMI-1a3
induced down-regulation of cyclins A, B1, D1, and E, suggesting
that the proportion of cells in S, G2, M, and late G1 phases were
reduced. Furthermore, HMI-1a3 exposure led to a pronounced
down-regulation of Rb, which is generally regulated by phosphor-
ylation/dephosphorylation and not by protein expression levels.
Down-regulation of Rb protein has been reported previously in
several cancer cell lines after exposures to an Mdm2 antagonist
nutlin-3 [33]. While down-regulation of Rb would be expected to
release E2F transcription factors and promote cell cycle progres-
sion, nutlin-3-induced down-regulation of Rb resulted in growth
arrest or apoptosis, depending on the cell type. The effect was
dependent on p53, linked to up-regulation of p21, and
independent of the E2F transcription factor. Our results with
HMI-1a3 are partially in agreement with these results; however,
we did not observe up-regulation of p21. Aberrant cell cycle
regulation in cervical cancer cell lines may explain the difference
[34]. In human papilloma virus (HPV)-positive cervical cancer
cells, such as HeLa cells, HPV E6 oncoprotein selectively targets
p53 for degradation via ubiquitin-protein ligase E6-AP instead of
Mdm2 [35], which is the main mediator of p53 degradation under
normal growth conditions. The tumor suppressor protein p53 on
the other hand regulates transcription of p21 [32], and thus the
instability of p53 in HeLa cells may explain why up-regulation of
p21 was not detected. Therefore, signaling pathways related to
HMI-1a3-induced down-regulation of Rb and cell cycle arrest in
HeLa cells are expected to be somewhat different than those
related to nutlin-3. Nevertheless, HMI-1a3-induced down-regula-
tion of cyclins provides evidence supporting the hypothesis that the
cell cycle may arrest in G1 phase before induction of cyclin E
expression.
The results of this study substantiate the potential of C1 domain
ligands in drug discovery. Targeting the regulatory domain of
PKC may be more beneficial than targeting the catalytic site in the
development of anticancer therapeutics. C1 domain-targeted PKC
activators may also provide potential therapeutic treatments for
Alzheimer’s disease [36]. Additionally, non-PKC DAG effectors
and the complicated signaling networks in which C1 domain-
containing proteins interact with each other provide numerous
opportunities for therapeutic discoveries. Furthermore, the results
presented in this article point out the potential of a novel group of
C1 domain ligands, dialkyl 5-(hydroxymethyl)isophthalates, as
Antiproliferative C1 Domain-Targeted Compounds
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antiproliferative agents. Although the binding affinities of
isophthalates for PKC isoenzymes are lower than those reported
for some other classes of synthetic C1 domain ligands such as
DAG lactones and benzolactams, cellular effects seem to appear at
similar concentrations. For example, a benzolactam derivative has
been reported to inhibit breast cancer cell proliferation with IC50
values of 20–30 mM depending on the cell line [37], and induction
of apoptosis by DAG lactones has been reported using
concentrations of 10–20 mM [38,39]. Natural products such as
ingenol-3-angelate and bryostatin 1 are notably more potent and
exert their cellular effects at nanomolar concentrations [12],
although bryostatin 1 alone has little antiproliferative or
proapoptotic efficacy [40]. Structural complexity of these naturally
occurring compounds however hinders their use in the develop-
ment of improved derivatives and therefore simpler templates are
acutely needed.
C1 domain-targeted small molecules present promising poten-
tial as drug candidates for the treatment of cancer and Alzheimer’s
disease. This study is the first report of cellular activity of a novel
group of C1 domain ligands, dialkyl 5-(hydroxymethyl)isophtha-
lates. We show here that active isophthalate derivatives induced
cell cycle arrest and non-necrotic, caspase-independent cell death
in HeLa human cervical cancer cells. The most potent
isophthalate derivative, HMI-1a3, exerted its effect at low
micromolar concentrations comparable to those reported with
other established synthetic C1 domain ligands. However, the
considerably simpler synthesis route makes the isophthalate
derivatives especially attractive candidates for further development
as lead compounds in drug development. In contrast, bryostatin 1
and PMA had no major effects of HeLa cell viability and
proliferation, and therefore their effects on the expression of cell
cycle markers were also distinct from those induced by HMI-1a3.
Even though the exact mechanism of action by which isophtha-
lates induce their effects in HeLa cells is for the present under




All reagents and chemicals were commercially available, except
for isophthalic acid derivatives that were designed and synthesized
at the Division of Pharmaceutical Chemistry, Faculty of
Pharmacy, University of Helsinki (Finland) [14]. Phorbol 12-
myristate-13-acetate (PMA) and bryostatin 1 were purchased from
Sigma-Aldrich (Steinheim, Germany). Cell culture solutions and
reagents were purchased from Invitrogen (Carlsbad, CA, USA)
except for Dulbecco’s modified Eagle’s medium (DMEM), which
was purchased from Sigma-Aldrich (Steinheim, Germany). The
reagent [methyl-3H] thymidine was purchased from Amersham
Pharmacia Biotech (Buckinghamshire, UK). Primary antibodies
against p21waf1/cip1, p27kip1, cyclin A, cyclin B1, cyclin D1, cyclin
E, retinoblastoma (Rb), phosphorylated form of Rb (Ser-795; pRb)
and b-actin were obtained from Cell Signaling Technology
(Danvers, MA, USA) as were HRP-linked secondary antibodies
anti-mouse IgG and anti-rabbit IgG. Anti-GAPDH monoclonal
antibody was purchased from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, USA). Precision Plus Protein Kaleidoscope
standard ladder (Bio-Rad Laboratories, Hercules, CA, USA) was
used as the sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) marker. Bicinchoninic acid (BCA) protein
assay reagents (BCA Protein Assay Kit) and enhanced chemilu-
minescence (ECL) reagents (SuperSignal-West-Pico-Chemilumi-
nescent-Substrate-Kit) were purchased from Pierce (Thermo
Fisher Scientific Inc., Rockford, IL, USA). The pan-caspase
inhibitor Boc-Asp(OMe) fluoromethyl ketone (BAF) was pur-
chased from Sigma-Aldrich (Steinheim, Germany).
Cell culture
HeLa cells (CCL-2) were acquired from American Type
Culture Collection (ATCC, Manassas, VA, USA) and cultured
in DMEM supplemented with 10% fetal bovine serum (FBS),
100 U/mL of penicillin, and 100 mg/mL of streptomycin. The
same medium was used for all treatments. Cultures were incubated
at 37uC in a humidified atmosphere of 5% carbon dioxide (CO2).
Cell viability tests
Cells were seeded onto 96-well plates (104 cells/well) and
incubated overnight to allow attachment. Cells were then treated
with test compounds in serum-supplemented DMEM (150 mL/
well) in a humidified, 5%-CO2 atmosphere at 37uC for 24 or 48 h
after which standard mitochondrial dehydrogenase activity (MTT)
and lactate dehydrogenase activity (LDH) tests were performed.
For LDH tests, 50 mL of medium from each well was transferred
into a new 96-well plate followed by addition of 50 mL of substrate
solution (1.3 mM b-nicotinamide adenine dinucleotide (b-NAD),
660 mM iodonitrotetrazolium, 54 mM L(+)-lactic acid, 280 mM
phenazine methosulphate, 0.2 M Tris-HCl (pH 8.2). Plates were
gently shaken for 10 min and incubated for another 20 min at
room temperature (RT). Fifty microliters of acetic acid (1 M) was
added to stop the reaction, and absorbance was measured at
490 nm (1 s/well). Background absorbance was measured in wells
containing medium alone. Spontaneous LDH release was
measured from untreated cells, and maximal LDH release was
determined from cells treated with 9% Triton X-100. For MTT
tests, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) was added to cells yielding a final concentration of
0.5 mg/mL, and plates were incubated for 2 h at 37uC in a 5%-
CO2 atmosphere. The medium was then aspirated and 200 mL of
DMSO was added to each well. Absorbance was measured at
550 nm with absorbance at 650 nm extracted as background.
Thymidine incorporation
HeLa cells were seeded onto 6-well plates (46105 cells/well) and
incubated overnight to allow cells to attach. Cells were treated
with compounds or vehicle, and 0.5 mCi/mL [methyl-3H]thymi-
dine was added to cells for the last 6 h of the incubation. After the
incubation, cells were washed three times with cold phosphate-
buffered saline (PBS). Ice-cold trichloroacetic acid (5% TCA) was
added and plates were incubated on ice for 10 min to extract
residual thymidine. The TCA solution was discarded, cells were
lysed with 0.1 M NaOH and radioactivity was measured.
Cell proliferation and morphology studies
HeLa cells were seeded onto 48-well plates (5000 cells/well) and
left to attach overnight. Cells were treated with compounds and
grown on a continuous cell culturing platform with integrated
optics for phase contrast imaging and machine vision technology
(Cell-IQH, Chip-man Technologies Ltd, Tampere, Finland) in a
humidified, 5%-CO2 atmosphere at 37uC for 72 h. Images were
captured automatically from 3–4 positions per well at 1 h
intervals. A protocol for examining cell numbers and morphology
of HeLa cells with Cell-IQ AnalyzerH software was created
according to manufacturer instructions. Briefly, segmentation
parameters were first adjusted to achieve optimal cell recognition.
Recognized cells were then classified into dead, dividing,
elongated and healthy HeLa cells. In addition, a class was added
Antiproliferative C1 Domain-Targeted Compounds
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for false recognitions of background. The protocol was tested
several times and optimized by analyzing a set of sample images to
verify classifications from images. The protocol was also tested for
accuracy by comparing classifications from a set of sample images
to classifications made manually by three researchers. The
protocol was then used to analyze images taken during Cell-IQH
experiments. Data were analyzed in three steps using Microsoft
Excel. First, false recognitions were subtracted from total cell
numbers. Second, total cell numbers were normalized to total cell
numbers in the same position at the beginning of the experiment
(i.e., the first image from each position). Finally, numbers of dead,
dividing, elongated and healthy cells were converted to percentage
of total cell number (false recognitions subtracted).
Determination of cell cycle markers by Western blotting
HeLa cells were seeded onto 6-well plates (46105 cells/well) and
left overnight to attach. Cells were treated with test compounds for
24 h, washed three times with PBS and lysed with 1% SDS in
1 mM of Tris-HCl (pH 7.0). The lysates were sonicated and
centrifuged at 16000 g for 15 min at 4uC. Pellets were discarded
and the protein concentration of the supernatant was measured
using a BCA protein assay kit according to manufacturer’s
instructions. Samples were diluted in Laemmli sample buffer at
equal concentrations and stored at 220uC until use. Twenty
micrograms of protein per lane were subjected to SDS-PAGE and
subsequently transferred to nitrocellulose membranes. Membranes
were washed for 5 min with 0.1% Tween 20 in Tris-buffered
saline (TTBS) and then blocked for 1 h with 5% nonfat milk
powder in TTBS (milk-TTBS) at RT. Membranes were incubated
at 4uC overnight with the primary antibody in milk-TTBS after
which they were washed for 35 min with TTBS. Membranes were
then incubated with horseradish peroxidase-conjugated secondary
antibody (goat anti-rabbit IgG or goat anti-mouse IgG, 1:2000 in
milk-TTBS) for 1 h at RT. After washing for 40 min with TTBS,
bands were visualized with ECL. GAPDH and b-actin bands were
used as controls to ensure equal protein loads among all wells.
Western blots were quantified by measuring the optical density of
the immunoreactive bands with Scion Image software (http://
scioncorp.com).
Statistical analysis
Data are expressed as the mean 6 SEM from at least three
independent experiments unless otherwise stated. MTT and Cell-
IQH results were analyzed using PASW Statistics 18 software
(SPSS Inc., Chicago, IL, USA). Concentration-response data were
analyzed using one-way analysis of variance (ANOVA) followed by
a Tukey’s honestly significant different (HSD) post hoc test.
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